AIM:CLIN

Stock Analysis Report

Executive Summary

Clinigen Group plc operates as a specialty pharmaceutical and services company.

Snowflake

Fundamentals

High growth potential and fair value.


Similar Companies

Share Price & News

How has Clinigen Group's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.3%

CLIN

0.9%

GB Life Sciences

2.0%

GB Market


1 Year Return

3.6%

CLIN

4.4%

GB Life Sciences

3.3%

GB Market

Return vs Industry: CLIN matched the UK Life Sciences industry which returned 4.4% over the past year.

Return vs Market: CLIN matched the UK Market which returned 3.3% over the past year.


Share holder returns

CLINIndustryMarket
7 Day-0.3%0.9%2.0%
30 Day-5.7%-5.6%-1.0%
90 Day-13.9%-7.3%-1.7%
1 Year4.3%3.6%4.7%4.4%8.3%3.3%
3 Year12.3%10.4%13.3%12.3%19.0%4.5%
5 Year94.8%90.0%35.1%33.4%38.4%8.4%

Price Volatility Vs. Market

How volatile is Clinigen Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Clinigen Group undervalued based on future cash flows and its price relative to the stock market?

43%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Undervalued: CLIN (£8.55) is trading below our estimate of fair value (£14.95)

Significantly Undervalued: CLIN is trading below fair value by more than 20%.


Price Based on Earnings

PE vs Industry: CLIN is poor value based on its PE Ratio (213.4x) compared to the Life Sciences industry average (39.3x).

PE vs Market: CLIN is poor value based on its PE Ratio (213.4x) compared to the UK market (16.4x).


Price Based on Expected Growth

Low PEG Ratio: CLIN is poor value based on its PEG Ratio (5.6x)


Price Based on Value of Assets

PB vs Industry: CLIN is good value based on its PB Ratio (2.6x) compared to the GB Life Sciences industry average (2.7x).


Next Steps

Future Growth

How is Clinigen Group expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

37.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: CLIN's forecast earnings growth (37.9% per year) is above the savings rate (1.2%).

Earnings vs Market: CLIN's earnings (37.9% per year) are forecast to grow faster than the UK market (12.3% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CLIN's revenue (9.2% per year) is forecast to grow faster than the UK market (4% per year).

High Growth Revenue: CLIN's revenue (9.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: CLIN's Return on Equity is forecast to be high in 3 years time (20.1%)


Next Steps

Past Performance

How has Clinigen Group performed over the past 5 years?

12.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CLIN's earnings have grown by 12.4% per year over the past 5 years.

Accelerating Growth: CLIN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: CLIN had negative earnings growth (-81%) over the past year, making it difficult to compare to the Life Sciences industry average (14%).


Return on Equity

High ROE: CLIN's Return on Equity (1.2%) is considered low.


Return on Assets

ROA vs Industry: CLIN's Return on Assets is below or equal to the Life Sciences industry average last year.


Return on Capital Employed

ROCE Improving: CLIN's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Clinigen Group's financial position?


Financial Position Analysis

Short Term Liabilities: CLIN's short term assets (£231.3M) do not cover its short term liabilities (£243.4M)

Long Term Liabilities: CLIN's short term assets (231.3M) do not cover its long term liabilities (384.3M)


Debt to Equity History and Analysis

Debt Level: CLIN's debt to equity ratio (76.6%) is considered high

Reducing Debt: CLIN's debt to equity ratio has increased from 24.6% to 76.6% over the past 5 years.

Debt Coverage: CLIN's debt is well covered by operating cash flow (20.3%).

Interest Coverage: CLIN's interest payments on its debt are well covered by EBIT (6.7x coverage).


Balance Sheet

Inventory Level: CLIN has a low level of unsold assets or inventory.

Debt Coverage by Assets: CLIN's debt is not covered by short term assets (assets are 0.7x debt).


Next Steps

Dividend

What is Clinigen Group's current dividend yield, its reliability and sustainability?

1.06%

Expected Dividend Yield


Upcoming Dividend Payment

Purchase Clinigen Group before the 'Buy Limit' to receive their next dividend payment.


Dividend Yield vs Market

company0.8%marketbottom25%2.0%markettop25%5.4%industryaverage0.9%forecastin3Years1.1%

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: CLIN's dividend (0.78%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (2%).

High Dividend: CLIN's dividend (0.78%) is low compared to the top 25% of dividend payers in the UK market (5.42%).

Stable Dividend: CLIN is not paying a notable dividend for the UK market, therefore no need to check if payments are stable.

Growing Dividend: CLIN is not paying a notable dividend for the UK market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: CLIN is not paying a notable dividend for .


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CLIN's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

What is the CEO of Clinigen Group's salary, the management and board of directors tenure and is there insider trading?

2.9yrs

Average management tenure


CEO

Shaun Chilton (51yo)

2.9yrs

Tenure

UK£2,558,000

Compensation

Mr. Shaun Edward Chilton has been the Chief Executive Officer of Clinigen Group Plc since November 11, 2016. Mr. Edward served as Group Deputy Chief Executive Officer of Clinigen Group Plc since July 22, 2 ...


CEO Compensation Analysis

Compensation vs. Market: Shaun's total compensation ($USD3.24M) is about average for companies of similar size in the UK market ($USD1.88M).

Compensation vs Earnings: Shaun's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Management Age and Tenure

2.9yrs

Average Tenure

51yo

Average Age

Experienced Management: CLIN's management team is considered experienced (2.9 years average tenure).


Board Age and Tenure

4.0yrs

Average Tenure

59yo

Average Age

Experienced Board: CLIN's board of directors are considered experienced (4 years average tenure).


Insider Trading

Insider Buying: CLIN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUK£34,82719 Sep 19
Nicholas Keher
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares3,900
Max PriceUK£8.93

Ownership Breakdown


Management Team

  • Shaun Chilton (51yo)

    CEO & Executive Director

    • Tenure: 2.9yrs
    • Compensation: UK£2.56m
  • Ivo Timmermans (59yo)

    Chief Medial Officer

    • Tenure: 3.7yrs
  • Nick Keher

    CFO & Director

    • Tenure: 0.6yrs
    • Compensation: UK£347.27k
  • Mark Corbett

    Managing Director of Global Access Division

    • Tenure: 6.3yrs
  • David Bryant

    Director of Corporate Development

    • Tenure: 5.3yrs
  • Johannes Willemse (51yo)

    Chief Commercial Officer

    • Tenure: 0yrs
  • Debra Ainge

    Chief Operating Officer

    • Tenure: 0yrs
  • Jessica Archer

    Global Human Resources Director

    • Tenure: 2.9yrs
  • Matt Parrish

    Head of Investor Relations

    • Tenure: 0yrs
  • Terry Walsh

    Senior Vice President of Clinical Trial Services

    • Tenure: 1.6yrs

Board Members

  • Ian Nicholson (59yo)

    Independent Non-Executive Director

    • Tenure: 7.1yrs
    • Compensation: UK£70.00k
  • Peter Allen (63yo)

    Independent Non-Executive Chairman

    • Tenure: 7.2yrs
    • Compensation: UK£143.00k
  • Alan Boyd (64yo)

    Non-Executive Director

    • Tenure: 0.9yrs
    • Compensation: UK£39.00k
  • Anne Hyland (58yo)

    Independent Non-Executive Director

    • Tenure: 1.8yrs
    • Compensation: UK£70.00k
  • Shaun Chilton (51yo)

    CEO & Executive Director

    • Tenure: 2.9yrs
    • Compensation: UK£2.56m
  • Nick Keher

    CFO & Director

    • Tenure: 0.6yrs
    • Compensation: UK£347.27k
  • John Hartup (68yo)

    Senior Independent Non-Executive Director

    • Tenure: 0yrs
    • Compensation: UK£70.00k
  • Johannes Willemse (51yo)

    Chief Commercial Officer

    • Tenure: 0yrs

Company Information

Clinigen Group Plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Clinigen Group Plc
  • Ticker: CLIN
  • Exchange: AIM
  • Founded: 2008
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£1.133b
  • Shares outstanding: 132.47m
  • Website: https://www.clinigengroup.com

Number of Employees


Location

  • Clinigen Group Plc
  • Pitcairn House
  • Crown Square
  • Burton-on-Trent
  • Staffordshire
  • DE14 2WW
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CLINAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPSep 2012
CLIG.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDSep 2012
78CDB (Deutsche Boerse AG)YesOrdinary SharesDEEURSep 2012

Biography

Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Com ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/13 22:46
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)